Purespring Therapeutics: Funding, Investors & Team (Oct 2026)
Purespring, which launched in November 2020 with £45 million of funding from Syncona Ltd, is the first company to be directly targeting the podocyte, a specialized kidney cell implicated in many kidney diseases, through AAV gene therapy. This approach is based on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, where he heads a world leading group researching glomerular diseases.
Purespring Therapeutics has raised $105M across 1 funding round on record, the most recent a Series B of $105M announced in Oct 2024.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Purespring Therapeutics Company Profile and Key Stats
Latest funding round on record: Oct 2024.
Purespring Therapeutics Funding Rounds
Purespring Therapeutics Founders and Leadership Team
Contact details for the Purespring Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Purespring Therapeutics Funding Compared to Other Biotechnology Startups
Purespring Therapeutics' latest round of $105M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Purespring Therapeutics in Biotechnology and London
Companies Similar to Purespring Therapeutics
Microbiotica develops treatments involving live bacteria found in the human microbiome, aiming to identify…
OMass Technologies is a drug discovery company exploiting novel mass spectrometry platforms to develop…
HydRegen, based in Oxford, UK, is a biotech firm that offers eco-friendly alternatives for the production of…
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug…
The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical…
Argonaute RNA company research projects build on existing intellectual property.
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
Purespring Therapeutics Funding FAQs
What does Purespring Therapeutics do?
Purespring, which launched in November 2020 with £45 million of funding from Syncona Ltd, is the first company to be directly targeting the podocyte, a specialized kidney cell implicated in many kidney diseases, through AAV gene therapy. This approach is based on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, where he heads a world leading group researching glomerular diseases.
How much funding has Purespring Therapeutics raised?
Purespring Therapeutics has raised $105M across 1 round on record. The most recent is a Series B of $105M announced in Oct 2024.
When did Purespring Therapeutics last raise funding?
Purespring Therapeutics' most recent funding round on record is a Series B of $105M, announced in Oct 2024.
Who founded Purespring Therapeutics?
FundedIQ lists Moin Saleem (Founder) at Purespring Therapeutics.
Where is Purespring Therapeutics headquartered?
Purespring Therapeutics is based in London, England, United Kingdom.
How many employees does Purespring Therapeutics have?
Purespring Therapeutics is in the 11-50 employee band.
How does Purespring Therapeutics' funding compare to other Biotechnology startups?
Purespring Therapeutics' latest round of $105M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Purespring Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Purespring Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.